Skip to content
Open access

Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhib

Oct 2026 · Journal of Gastrointestinal Oncology · Vol 17 · 0 citations · 21 references
Medicine

Abstract

Background Reliable pretreatment tools to identify treatment-naïve patients with intermediate-to-advanced hepatocellular carcinoma (HCC) who may benefit from this combination are lacking. We developed and internally validated a clinical-radiomics model based on pretreatment T2-weighted fat-suppressed magnetic resonance imaging (MRI) for predicting 1-year overall survival (OS). Methods This retrospective, single-center cohort study included 85 treatment-naïve patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC treated with transarterial chemoembolization (TACE) plus targeted therapy and immune checkpoint inhibitors between December 2021 and April 2024. The last follow-up was April 1, 2026. The primary endpoint was 1-year OS status (death within 12 months vs. survival ≥12 months). Patients were randomly divided into a training set (70%) and a held-out test set (30%) using stratified sampling. Three-dimensional tumor volumes were manually segmented on pretreatment axial T2 spectral attenuated inversion recovery images. Features were first filtered for intra- and interobserver reproducibility, then selected using univariable screening and least absolute shrinkage and selection operator (LASSO) regression before being entered into the machine-learning models. The optimal model was selected via fivefold cross-validation in the training set and evaluated in a held-out test set through use of discrimination, calibration, decision curve analysis, and Shapley additive explanations. Results A total of 2,525 radiomics features were extracted, and four final predictors were retained: maximum tumor diameter and three filtered radiomics features. Gradient boosting machine (GBM) achieved the highest mean cross-validation area under the receiver operating characteristic curve (AUC) (0.818±0.079). In the held-out test set, the combined GBM model yielded an AUC of 0.91 [95% confidence interval (CI): 0.87–0.93], accuracy of 84.6% (95% CI: 79.3–88.9%), sensitivity of 81.8% (95% CI: 72.2–89.0%), and specificity of 86.7% (95% CI: 79.1–92.1%); the Brier score was 0.04. Decision curve analysis suggested a net clinical benefit across a broad range of threshold probabilities. Conclusions A pretreatment T2-weighted fat-suppressed MRI-based clinical-radiomics model demonstrated promising performance for predicting 1-year OS in treatment-naïve patients with BCLC stage B/C HCC receiving TACE plus targeted therapy and immune checkpoint inhibitors. However, this single-center finding requires external validation before clinical implementation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.